KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Leases: 2009-2016

Historic Capital Leases for Rigel Pharmaceuticals (RIGL) over the last 3 years, with Dec 2016 value amounting to $238,000.

  • Rigel Pharmaceuticals' Capital Leases fell 93.12% to $238,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $238,000, marking a year-over-year decrease of 93.12%. This contributed to the annual value of $238,000 for FY2016, which is 93.12% down from last year.
  • Rigel Pharmaceuticals' Capital Leases amounted to $238,000 in Q4 2016, which was down 77.63% from $1.1 million recorded in Q3 2016.
  • Rigel Pharmaceuticals' 5-year Capital Leases high stood at $6.5 million for Q4 2014, and its period low was $238,000 during Q4 2016.
  • Over the past 3 years, Rigel Pharmaceuticals' median Capital Leases value was $3.5 million (recorded in 2015), while the average stood at $3.4 million.
  • Data for Rigel Pharmaceuticals' Capital Leases shows a maximum YoY slumped of 93.12% (in 2016) over the last 5 years.
  • Rigel Pharmaceuticals' Capital Leases (Quarterly) stood at $6.5 million in 2014, then plummeted by 46.49% to $3.5 million in 2015, then crashed by 93.12% to $238,000 in 2016.
  • Its last three reported values are $238,000 in Q4 2016, $1.1 million for Q3 2016, and $1.9 million during Q2 2016.